HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
HTL announces that Montagu, a leading private equity firm, has acquired a majority stake of HTL previously held by Bridgepoint. The other minority shareholders, Naxicap and Téthys Invest, will keep their shares in the company.
The arrival of this new shareholder symbolizes the international success of a company that has become the world leader in the development and production of pharmaceutical grade biopolymers.
We’re pleased to share our second CSR report, highlighting the actions and commitments we carried out throughout 2024.
A Global Scientific Gathering Dedicated to Hyaluronic Acid Innovation.
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.